Julia Cunningham, MD
Hematology & Oncology · Washington, DCNPI 1487949335
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by AstraZeneca at 40.8% of the total. That places this record below the midpoint for hematology & oncology clinicians in DC, where the typical reported total is $4,025.
Across 21 payments — averaging $38.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$330
- Bioverativ Therapeutics Inc.$120
- Novartis$90
- Karyopharm Therapeutics Inc.$75
- Johnson & Johnson$40
- Merck$27
- plus $126 from 6 others
Across 96 payments — averaging $3608.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmaessentia USA Corporation$144K
- Incyte Corporation$72K
- Karyopharm Therapeutics Inc.$51K
- Ionis Pharmaceuticals, Inc.$45K
- CTI Biopharma Corp.$18K
- Genentech, Inc.$9K
- plus $7K from 1 others
What the payments were for
- Speaking & faculty fees$42052%
- Food & beverage$37346%
- Education$152%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $330 |
| Bioverativ Therapeutics Inc. | 2 | $120 |
| Novartis | 4 | $90 |
| Karyopharm Therapeutics Inc. | 2 | $75 |
| Johnson & Johnson | 2 | $40 |
| Merck | 1 | $27 |
| Bristol Myers Squibb | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Accord Healthcare, Inc. | 1 | $19 |
| Puma Biotechnology, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$808 in reported general payments places this provider in the 35th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 24 | $345,941 |
| BrukinsaZanubrutinib | 22 | $284,683 |
| PromactaEltrombopag Olamine | 11 | $213,566 |
| ImbruvicaIbrutinib | 13 | $213,145 |
| EliquisApixaban | 53 | $46,517 |
| XareltoRivaroxaban | 35 | $31,548 |
| Enoxaparin Sodium | 26 | $11,145 |
| Hydroxyurea | 30 | $765 |
| Warfarin Sodium | 24 | $91 |
| MethotrexateMethotrexate Sodium | 13 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $330 | $345,94124 claims |
| NovartisPromacta | $90 | $213,56611 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $23 | $213,14513 claims |
| Johnson & JohnsonXarelto | $40 | $31,54835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.